AYTU
Aytu BioPharma, Inc.
AYTU's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over AYTU overall, supported by stronger fundamentals and stronger modeled upside.
AYTU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Stable | |
| Strong |
AYTU's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AYTU PE Valuation
AYTU has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AYTU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect AYTU's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AYTU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.66 | +$0.96 |
| Q1 2026 | -$4.08 | -$3.05 |
| Q4 2025 | -$3.34 | -$1.58 |
| Q3 2025 | -$2.55 | -$1.01 |
| Q2 2025 | -$2.62 | +$0.25 |
| Q1 2025 | -$1.03 | +$1.76 |
| Q4 2024 | -$1.76 | +$2.44 |
| Q3 2024 | -$1.54 | +$4.77 |
AYTU is still losing money, but far less than before: $1.66 per share over the past year, against $85.40 at its worst in early 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AYTU on earnings quality, reporting a profit while its opponent remains loss making.
AYTU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.1M | +6.4% |
| Q1 2026 | $12.4M | -33% |
| Q4 2025 | $15.2M | -6.5% |
| Q3 2025 | $13.9M | -16% |
| Q2 2025 | $15.1M | -16% |
| Q1 2025 | $18.5M | +2.6% |
| Q4 2024 | $16.2M | -29% |
| Q3 2024 | $16.6M | -25% |
AYTU's revenue is recovering but still below its 2023 peak: $16M last quarter, up 6.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4.8% | +46 points |
| Q1 2026 | -33% | -46 points |
| Q4 2025 | -13% | -2.5 points |
| Q3 2025 | -11% | -5.2 points |
| Q2 2025 | -50% | -30 points |
| Q1 2025 | 13% | +27 points |
| Q4 2024 | -10% | -21 points |
| Q3 2024 | -5.6% | +1.2 points |
AYTU's operating margin was −4.8% last quarter, up 46 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AYTU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AYTU on profitability, with a higher operating margin.
AYTU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.4M | +58% |
| Q1 2026 | -$4.2M | +$2.3M |
| Q2 2025 | $2.8M | +$3.6M |
| Q1 2025 | -$6.5M | -$6.3M |
| Q2 2024 | -$788K | -108% |
| Q1 2024 | -$254K | +$2.7M |
| Q4 2023 | -$135K | +$2.3M |
| Q3 2023 | -$211K | +$8.9M |
AYTU's free cash flow has turned positive after five years mostly in the red: $3M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AYTU on cash generation, producing positive trailing cash flow while its opponent burns cash.
AYTU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +1.8M shares |
| 1 year | +50% | +4.1M shares |
| 3 years | +296% | +9.2M shares |
| 5 years | +6884% | +12.1M shares |
AYTU has 12M diluted shares, up 50% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AYTU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AYTU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | -1.8x | Net Cash |
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -3.8x | Net Cash |
AYTU has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AYTU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.9 | Neutral |
| Stochastic | 8.0 | Oversold |
AYTU's weekly RSI is 36 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AYTU PE vs Healthcare Sector
AYTU has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AYTU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.98 | 9.6% below |
| 20 week MA | $2.12 | 16% below |
| 50 week MA | $2.32 | 23% below |
| 100 week MA | $2.08 | 14% below |
| 200 week MA | $2.27 | 21% below |
AYTU is in a downtrend: it's below all five of its weekly moving averages, and 21% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AYTU on trend strength, trading above more of its moving averages.
AYTU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $196.0 | $122.4 | -38% |
| 2021 | $122.4 | $30.4 | -75% |
| 2022 | $30.4 | $3.80 | -88% |
| 2023 | $3.80 | $2.84 | -25% |
| 2024 | $2.84 | $1.52 | -46% |
| 2025 | $1.52 | $2.45 | +61% |
| 2026 YTD | $2.45 | $1.79 | -27% |
AYTU has finished lower in five of the last six years. It's down 27% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AYTU on returns for 2026, with the stronger performance.